SCHEMBL2256753

SCHEMBL2256753

COC(=O)c1cccc(-c2ccc(OCc3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.49
RXRA P19793 5/20 0.48
NR1H2 P55055 5/20 0.48
NR1H3 Q13133 5/20 0.48
MRGPRX4 Q96LA9 2/20 0.43
SDHB P21912 1/20 0.40
SYK P43405 1/20 0.40
POLB P06746 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39
TRPV1 Q8NER1 3/20 0.39
PDK2 Q15119 1/20 0.39
SLC16A3 O15427 1/20 0.39
LIFR P42702 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2258608 0.91 RXRA (0.49) NR1H4RXRANR1H2NR1H3SYK
SCHEMBL2257758 0.91 NR1H4 (0.50) NR1H4RXRANR1H2NR1H3MRGPRX4
SCHEMBL2255712 0.89 NR1H2 (0.46) NR1H4RXRANR1H2NR1H3MRGPRX4
SCHEMBL2255063 0.87 HPGD (0.48) NR1H4RXRANR1H2NR1H3BCL2L1
SCHEMBL2257412 0.86 POLB (0.45) RXRANR1H2NR1H3POLB
SCHEMBL2257146 0.86 MAOB (0.47) RXRANR1H2NR1H3POLBTRPV1
SCHEMBL2256982 0.86 RXRA (0.50) RXRANR1H2NR1H3SYKSLC16A3
SCHEMBL2260114 0.85 RXRA (0.49) RXRANR1H2NR1H3TRPV1SLC16A3
SCHEMBL2258160 0.85 RXRA (0.44) RXRANR1H2NR1H3MRGPRX4POLB
SCHEMBL3473530 0.85 RXRA (0.66) RXRANR1H2NR1H3SDHBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121621-B1 LXR AND FXR MODULATORS EXELIXIS PATENT CO LLC (US) 2014-05-07 EP disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed
EP-2121621-A1 LXR AND FXR MODULATORS Exelixis, Inc. (US) 2009-11-25 EP disclosed
WO-2008073825-A1 LXR AND FXR MODULATORS EXELIXIS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069367-A1 LXR and FXR Modulators NR1H3, NR1H2, NR1H4 NR1H4 3/4885RXRA 8/4885NR1H2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.